RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)

Ontario Industry Updates
Written By Guest User
Eliav-Shaked-RetiSpec_logo.jpg

RetiSpec Inc. announced that it has received an award from the Alzheimer's Drug Discovery Foundation (ADDF) to fund the accelerated development of retinal imaging technology for the early detection of Alzheimer's disease. The award of up to USD $500,000 includes a direct investment in the company. It is an investment through the ADDF's Diagnostics Accelerator initiative.

Guest User
Previous

Synaptive Announces Co-Marketing Collaboration with Stryker, Expansion Into Spine Market
Next

NERv Announces $1M CAD in Pre-Seed Round